Skip to main content
Clinical Trials/NCT03026634
NCT03026634
Completed
Not Applicable

Prevalence and Dynamic of Sleep-disordered Breathing in Patients Pre and Post Heart Transplantation - a Prospective Single Center Trial

Heart and Diabetes Center North-Rhine Westfalia1 site in 1 country500 target enrollmentJanuary 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sleep Disordered Breathing Central
Sponsor
Heart and Diabetes Center North-Rhine Westfalia
Enrollment
500
Locations
1
Primary Endpoint
Apnea Hypopnea Index
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Sleep-disordered breathing is believed to appear at a high prevalence in end-stage heart failure patients and the presence of sleep-disordered breathing has been associated with increased mortality. This study is designed to investigate prevalence and dynamics of sleep-disordered breathing in end-stage heart failure patients pre and post heart transplantation.

Detailed Description

Sleep-disordered breathing is believed to appear at a high prevalence in end-stage heart failure patients and the presence of sleep-disordered breathing has been associated with increased mortality. This study is designed to investigate prevalence and dynamics of sleep-disordered breathing in end-stage heart failure patients pre and post heart transplantation, as this topic is hardly studied yet and previous reports suggest changes in the entity of sleep-disordered breathing through heart transplantation. The circumstances and the impact of sleep-disordered breathing or residuals in heart transplant patients is not well understood yet and will be subject of this study.

Registry
clinicaltrials.gov
Start Date
January 1, 2017
End Date
December 31, 2020
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Heart and Diabetes Center North-Rhine Westfalia
Responsible Party
Principal Investigator
Principal Investigator

Henrik Fox, MD

Cardiologist

Heart and Diabetes Center North-Rhine Westfalia

Eligibility Criteria

Inclusion Criteria

  • End-stage heart failure patients assigned and eligible for heart transplantation

Exclusion Criteria

  • heart failure patients not eligible for heart transplantation

Outcomes

Primary Outcomes

Apnea Hypopnea Index

Time Frame: 30 days after heart transplantation

Change in Apnea Hypopnea Index (AHI /h) before and after heart transplantation

Secondary Outcomes

  • Hypopnea Index(30 days after heart transplantation)
  • Time SaO2 < 90 (%)(30 days after heart transplantation)
  • Respiration cycle length(30 days after heart transplantation)
  • Right heart catheter(30 days after heart transplantation)
  • Apnea Index(30 days after heart transplantation)
  • Health Questionnaires(30 days after heart transplantation)
  • Oxygen Desaturation Index(30 days after heart transplantation)
  • Blood gas analysis(30 days after heart transplantation)

Study Sites (1)

Loading locations...

Similar Trials